Table 2 Production cost and profits made from lamivudine 150 mg plus zidovudine 300 mg tablets
Materials cost | Zidovudine | Lamivudine |
|---|---|---|
Daily dose (mg) | 600 | 300 |
Amount of API per person-year in kg (daily dose in mg X 365 days/1.000.000) | 0.219 | 0.1095 |
Cost of API (per kg) (lowest quote in the 2010 WHO survey) | 315 | 150 |
Cost of API per person-year (Amount of API per person-year in kg X cost of API per kg) | 69.0 | 16.4 |
Cost of API per person-year of both APIs combined | 85.4 | |
Number of tablets/day required to administer a daily dose of zidovudine plus lamivudine | 2 | |
Cost of excipients and packaging (3.21 per 365 tablets X number of tablets/day X 365 days) | 6.4 | |
Subtotal materials cost per person-year | 91.8 | |
Non-materials cost per person-year (according to both scenarios) | Indian manufacturer | Publicly owned manufacturer |
Indian manufacturer: 78.3% of materials cost | 71.9 | - |
Publicly owned manufacturer: 23.4 X number of tablets/day | - | 46.8 |
Total production cost per person-year | Â | Â |
Materials cost PLUS non-materials cost | 163.7 | 138.6 |
Median price paid by low income countries per person- year in 2010 | 101.4 | |
Profit or loss per person-year at API cost quoted to WHO in 2010 | −62.3 | −37.2 |
Profit or loss per person-year when API cost is: | Â | Â |
20% less than quoted to WHO | −31.9 | −20.1 |
40% less than quoted to WHO | −1.4 | −3.1 |
60% less than quoted to WHO | 29.0 | 14.0 |